Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Naringin Inhibits Tumor Growth and Reduces Interleukin-6 and Tumor Necrosis Factor alpha Levels in Rats with Walker 256 Carcinosarcoma|
|Author:||Camargo, Camila A.|
Gomes-Marcondes, Maria Cristina C.
Wutzki, Nathalie C.
|Abstract:||The flavonoid naringin is a polyphenolic compound that naturally occurs in citrus. Patients with cancer generally present features of malnutrition and cachexia. Levels of the proinflammatory cytokines tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) are raised in patients with cancer. This study was designed to analyze the in vivo effect of naringin in the therapeutic treatment of rats bearing Walker 256 carcinosarcoma (W256). Rats were treated intraperitoneally with different doses of naringin (10, 25 and 35 mg/kg), for 50 days. At 25 mg/kg, naringin inhibited tumor growth by similar to 75%. With this treatment, TNF-alpha and IL-6 levels decreased (p<0.05) in comparison with the control. In addition, two rats presented complete tumor regression. Inhibition of tumor growth, survival increase and the reduction of TNF-alpha and IL-6 levels in rats bearing W256 treated with naringin strongly suggest that this compound has potential as an anticarcinogenic drug.|
Walker 256 carcinosarcoma
tumor necrosis factor alpha and interleukin-6
|Editor:||Int Inst Anticancer Research|
|Citation:||Anticancer Research. Int Inst Anticancer Research, v.32, n.1, p.129-133, 2012|
|Appears in Collections:||IB - Artigos e Outros Documentos|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.